Akeso, Inc. (HKG:9926)
85.10
-7.70 (-8.30%)
Oct 22, 2026, 2:05 PM HKT
Akeso Revenue
Akeso had revenue of 1.81B CNY in the half year ending June 30, 2026, with 76.21% growth. This brings the company's total for the last twelve months to 3.45B, up 37.43% year-over-year. In the year 2025, Akeso had annual revenue of 3.06B with 43.90% growth. That makes Akeso the 11,138th largest company in the world by revenue and 673rd in Hong Kong.
Revenue (ttm)
3.45B CNY
Revenue Growth
+37.43%
P/S Ratio
21.93
Revenue / Employee
845.28K CNY
Employees
4,082
Market Cap
80.09B HKD
Revenue by Geography
- Mainland China 2.70B 88.4%
- United States of America (USA) 338.52M 11.1%
- Other Regions 17.50M 0.6%
Fiscal year ended Dec 31, 2025 See the full Akeso breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.06B | 932.33M | 43.90% |
| Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
| Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
| Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
| Dec 31, 2021 | 225.63M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 38.91B |
| WuXi Biologics | 27.27B |
| 3SBio | 20.63B |
| Innovent Biologics | 18.13B |
| RemeGen | 9.24B |
| Shanghai Henlius Biotech | 8.58B |
| Genscript Biotech | 6.63B |
| Shanghai Junshi Biosciences | 3.49B |
Akeso News
- 2 days ago - Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab - PRNewsWire
- 9 days ago - Akeso Doses First Patient In Phase 3 Cadonilimab Study For MSI-H Colon Cancer - Nasdaq
- 10 days ago - Akeso announces first patient dosed in Phase III study of cadonilimab - TheFly
- 22 days ago - AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows - South China Morning Post
- 24 days ago - Akeso Enrolls First Patient In Phase 3 Cadonilimab Head-To-Head Gastric Cancer Trial - Nasdaq
- 24 days ago - Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer - PRNewsWire
- 4 weeks ago - Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals - CNBC
- 4 weeks ago - Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate - PRNewsWire